Novo Disappoints With No Liraglutide News, But Growth Is Strong

Novo delivered strong first-half results, but provided little further clarity on liraglutide's progress at FDA.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet